Dermatology · Clinical trials
Prurigo Nodularis Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About prurigo nodularis — and why its trials are hard
Prurigo nodularis (PN) is a chronic, intensely pruritic inflammatory skin disease characterized by firm, hyperkeratotic nodules distributed symmetrically on the extensor limbs and trunk, arising and perpetuated by a self-reinforcing itch-scratch cycle. Its pathophysiology involves type 2 immune signaling (IL-4, IL-13, IL-31), neural sensitization, and dermal fibrosis, linking skin inflammation to chronic neuropathic and pruritoceptive itch. The condition carries a heavy quality-of-life and mental-health burden and had no FDA-approved therapy for years, relying on topical steroids, antihistamines, gabapentinoids, and phototherapy. That changed with the arrival of targeted biologics. Dupilumab, blocking IL-4 and IL-13 signaling, became the first FDA-approved treatment in 2022, followed by nemolizumab, an IL-31 receptor alpha antagonist, in 2024. Pivotal trials center on the Worst-Itch Numeric Rating Scale (WI-NRS/PP-NRS), with a 4-point or greater reduction as the key itch endpoint, alongside IGA-based lesion clearance measures.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Dupilumab (Dupixent) | 2022 | Adults with prurigo nodularis (first FDA-approved therapy) | PRIME and PRIME2 (Phase 3, Nature Medicine 2023) | At least a 4-point reduction in Worst-Itch NRS at week 24 (PRIME) / week 12 (PRIME2) | About 60% of dupilumab patients achieved a 4-point or greater itch improvement versus roughly 18-20% on placebo |
| Nemolizumab (Nemluvio) | 2024 | Adults with prurigo nodularis | OLYMPIA 1 and OLYMPIA 2 (Phase 3; OLYMPIA 2 in NEJM 2023) | At least a 4-point reduction in Peak Pruritus NRS and IGA success at week 16 | Roughly 56-58% achieved a 4-point or greater itch reduction versus about 16-20% on placebo, with significantly higher IGA clearance |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in prurigo nodularis development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Serlopitant — Two Phase 3 trials in prurigo nodularis pruritus (Menlo Therapeutics, reported 2020) | Failed to meet the primary endpoint of significant reduction in pruritus versus placebo across the pivotal studies | The oral NK-1 receptor antagonist showed a high placebo response and insufficient separation, and neurokinin-1 blockade alone did not adequately address the type 2 inflammatory drivers of PN itch |
Choosing the right endpoint
Primary endpoints that matter in prurigo nodularis trials
- WI-NRS / PP-NRS 4-point response — Proportion achieving at least a 4-point reduction in worst-itch/peak-pruritus numeric rating; the key patient-reported itch endpoint
- IGA success — Investigator Global Assessment of clear/almost clear skin, reflecting nodule clearance
- Sleep and quality-of-life measures — Sleep NRS and DLQI capturing the downstream burden of chronic itch
- Combined itch and lesion response — Composite endpoints requiring both meaningful itch reduction and skin clearance
How iNGENū runs prurigo nodularis trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Prurigo Nodularis clinical trials — FAQs
What was the first FDA-approved drug for prurigo nodularis?
How is treatment success measured?
How does nemolizumab differ from dupilumab?
Ready to discuss your prurigo nodularis trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal